Aklief Shortage: What Providers and Prescribers Need to Know in 2026

Aklief (Trifarotene) cream 0.005% has established itself as a valuable addition to the topical retinoid armamentarium since its FDA approval in October 2019. As the first new retinoid molecule for acne in over 20 years — and the only topical retinoid specifically approved for both facial and truncal acne — it fills a genuine clinical niche.

However, patient access remains a persistent challenge. While Aklief is not in a formal supply shortage, providers across dermatology and primary care report that patients frequently struggle to fill their prescriptions. This briefing outlines the current landscape and offers practical strategies for prescribers.

Timeline: Aklief Approval and Market Position

• October 2019: FDA approves Aklief (Trifarotene) cream 0.005% for acne vulgaris in patients ≥9 years. First new retinoid molecule in 20+ years.
• 2022: Supplemental FDA approval for treatment of fine lines and wrinkles on the face in adults.
• 2019–present: No generic version has entered the market. Trifarotene remains exclusively available as the brand-name product from Galderma Laboratories.
• 2026: No FDA-reported supply shortage. Access difficulties are driven by cost, insurance coverage gaps, and pharmacy stocking patterns.

Prescribing Implications

Clinical Differentiation

Aklief's selective RAR-γ agonism differentiates it from non-selective retinoids (Tretinoin) and RAR-β/γ agonists (Adapalene, Tazarotene). Key clinical considerations:

• Truncal acne: Aklief is the only topical retinoid with specific FDA-approved labeling for face and trunk (chest, shoulders, back). This remains its most distinctive clinical advantage.
• Tolerability: The selective RAR-γ mechanism may contribute to improved tolerability compared to Tretinoin, though head-to-head data is limited.
• Dosing simplicity: Single strength (0.005%), once-daily application via airless pump. Available in 45g and 75g sizes.
• Pregnancy considerations: Not formally pregnancy category X (the old category system was replaced), but animal reproduction studies showed adverse fetal effects at supratherapeutic exposures. Counsel patients of reproductive potential accordingly.

Step Therapy and Prior Authorization

Prior authorization is required by the vast majority of commercial payers. Typical PA criteria include:

• Documented trial and failure of at least one generic retinoid (usually Tretinoin or Adapalene)
• Some plans require failure of two agents before approving Aklief
• Documentation of clinical response (or lack thereof) to prior therapy

Approximately 80% of commercial plans include Aklief in their formulary, but coverage often comes with tier 3 or specialty tier placement. Only about 33% of ACA marketplace plans cover Aklief. Medicaid coverage is inconsistent across states.

For a patient-facing version of this information, see: Aklief Shortage Update: What Patients Need to Know.

Availability Picture

Aklief is not on the FDA Drug Shortage Database. Manufacturing supply from Galderma appears stable. However, real-world availability is affected by:

• Pharmacy stocking: Many retail chain pharmacies do not stock Aklief routinely due to low turnover and high per-unit cost ($760–$1,080 retail). Special ordering adds 1–3 business days.
• Independent and specialty pharmacies: More likely to stock dermatology-focused products and may offer faster turnaround.
• Mail-order pharmacies: Generally have consistent availability from centralized distribution.

Providers can help patients locate pharmacies with stock by directing them to Medfinder for Providers, which offers real-time pharmacy availability data.

Cost and Access Landscape

Current Pricing (2026)

• Average retail price: $760–$1,080 per 45g pump
• Coupon card pricing (GoodRx/SingleCare): $600–$700
• Galderma CareConnect (commercially insured): As low as $20 per fill
• Galderma CareConnect (cash-paying/not covered): No more than $90 per fill
• Generic: Not available

Galderma CareConnect Savings Program

The manufacturer savings card is the single most impactful tool for reducing patient out-of-pocket costs. Key details for prescribers:

• Eligible for commercially insured patients and cash-paying patients
• Not eligible: Medicare, Medicaid, Tricare, VA, or other government-funded insurance
• Up to 15 uses per calendar year
• Enrollment: galdermacc.com/patients or 855-280-0543
• Consider having enrollment information available in your office for patients at the point of prescribing

Patient Assistance Programs

Galderma does not currently offer a formal patient assistance program (PAP) for uninsured or underinsured patients. For patients who cannot afford Aklief even with coupon cards, consider:

• NeedyMeds.org and RxAssist.org for third-party assistance databases
• Switching to a generic retinoid alternative (Tretinoin at $10–$50, or OTC Adapalene at $10–$15)

Tools and Resources for Your Practice

1. Medfinder for Providers: medfinder.com/providers — Help patients find pharmacies with Aklief in stock. Integrates with clinical workflows.
2. Galderma CareConnect: Keep savings card materials in your office. Proactively mention the program when prescribing Aklief.
3. Prior Authorization Templates: Streamline PA submissions by documenting prior retinoid trials clearly in the chart. Include specific agents tried, duration of use, and documented clinical response.
4. Patient Education: Direct patients to evidence-based resources about their medication. Medfinder offers patient-friendly guides including What Is Aklief? and Aklief Side Effects.

Looking Ahead

Several factors may influence Aklief access in the coming years:

• Generic entry: No confirmed timeline, but patent expirations will eventually open the door to generic Trifarotene. This could dramatically improve access and reduce costs.
• Expanded indications: The 2022 approval for fine lines/wrinkles may increase prescribing volume, which could improve pharmacy stocking patterns.
• Formulary changes: As clinical evidence accumulates and prescribing volume grows, payers may relax prior authorization requirements.
• Telehealth expansion: Virtual dermatology visits continue to increase access to prescribers, particularly for patients in underserved areas.

Final Thoughts

Aklief represents a meaningful clinical advance in topical retinoid therapy, particularly for truncal acne. The access challenges it faces — cost, insurance barriers, pharmacy stocking — are systemic issues that affect many brand-name dermatology products. Providers can make a significant difference by proactively connecting patients with savings programs, choosing pharmacies strategically, and using tools like Medfinder to streamline the access process.

For provider-specific guidance on helping patients find medications, see: How to Help Your Patients Find Aklief in Stock.